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Combinational therapyIt is well-established that cannabinoids exert palliative effects on some cancer-associated symptoms. In addition
evidences obtained during the last ﬁfteen years support that these compounds can reduce tumor growth in
animal models of cancer. Cannabinoids have been shown to activate an ER-stress related pathway that leads to
the stimulation of autophagy-mediated cancer cell death. In addition, cannabinoids inhibit tumor angiogenesis
and decrease cancer cell migration. The mechanisms of resistance to cannabinoid anticancer action as well as
the possible strategies to develop cannabinoid-based combinational therapies to ﬁght cancer have also started
to be explored. In this review we will summarize these observations (that have already helped to set the bases
for the development of the ﬁrst clinical studies to investigate the potential clinical beneﬁt of using cannabinoids
in anticancer therapies) and will discuss the possible future avenues of research in this area.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Δ9-tetrahydrocannabinol (THC), the main active component of
Cannabis sativa exerts its effects by mimicking endogenous substances –
the endocannabinoids anandamide (Devane et al., 1992) and 2-
arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al.,
1995) – that bind speciﬁc cannabinoid receptors located in the plasma
membrane (Pertwee et al., 2010). Two major cannabinoid-speciﬁc
receptors – CB1 and CB2 – have been identiﬁed (Matsuda et al., 1990;
Munro et al., 1993). The transient receptor potential cation channel
subfamily Vmember 1 (TRPV1), the orphan G protein-coupled receptor
GPR55 and peroxisome proliferator-activated receptors (PPARs) have
been proposed to act as endocannabinoid receptors, although theirthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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still a matter of debate (Pertwee et al., 2010). Most of the cannabinoids
effects in the central nervous system rely on CB1 receptor activation
(Pertwee et al., 2010), Nevertheless expression of CB1 receptor is not
restricted to the central nervous system and this receptor is widely
expressed in many different locations in the organism (Pertwee et al.,
2010) The CB2 receptor was initially described to be present in the
immune system (Pertwee et al., 2010), although different studies have
shown that it is also present in cells from other origins including astro-
cytes and certain populations of neurons (Atwood and Mackie, 2010;
Fernandez-Ruiz et al., 2007). Of note, expression of CB1 and CB2 receptors
occurs in many types of cancer cells, an event that not necessarily corre-
lates with the expression of these receptors in non-transformed cells
from the tissue from which cancer cells originated (Fernandez-Ruiz
et al., 2007; Guzman et al., 2006; Sarfaraz et al., 2008).
The endocannabinoid system – constituted by the endocannabinoids,
their receptors and the proteins involved in the synthesis, transport and
degradation of endocannabinoids – exerts numerous regulatory
functions in the organism (Katona and Freund, 2008); (Pacher et al.,
2006; Pertwee, 2009). Accordingly, the pharmacological manipulation
of the endocannabinoid system is being investigated for the treatment
of many different diseases. In a cancer context, cannabinoids have
been shown to alleviate nausea and vomit induced by chemotherapy
(Guzman, 2003; Pertwee, 2009) and several cannabinoid-based medi-
cines [Marinol (THC) and Cesamet (nabilone, a synthetic analogue of
THC)] are approved for this purpose. Cannabinoids also inhibit pain,
and Sativex (a standardized cannabis extract) has been approved in
Canada for the treatment of cancer-associated pain. Other potential pal-
liative effects of cannabinoids in oncology include appetite stimulation
and attenuation of wasting (Pertwee et al., 2010).
In addition to these palliative actions of cannabinoids in cancer
patients, THC and other cannabinoids exhibit antitumor effects in
animal models of cancer (Guzman, 2003; Sarfaraz et al., 2008);
(Pisanti et al., 2013; Velasco et al., 2012).
2. Endocannabinoid system: role in tumor generation
and progression
A relatively large body of data has accumulated during the last
decade about the role of endocannabinoid system in tumor generation
and progression (see Table 1 for a brief summary of some of theseTable 1
Changes in the expression of cannabinoid (CB) receptors or endocannabinoids (ECB)-degradin
Tumor type CB receptors or ECB degrading enzymes
Hodgkin lymphoma CB1 levels increased
Non-Hodgkin lymphoma CB1 levels increased
Chemically-induced cellular hepatocarcinoma CB1 levels increased
Hepatocellular carcinoma CB1 and CB2 expression correlates with im
with hepatocellular carcinoma
Human epithelial ovarian tumors CB1 levels increased. Correlation with dis
Stage IV colorectal cancer CB1 levels are a factor of bad prognosis fo
Colon cancer CB1 levels decreased, CB1 genetic ablatio
colon carcinomas
Pancreatic cancer CB1 and CB2 levels increased and MAGL a
associated with bad prognosis
Prostate cancer CB1 levels increased associated with seve
prognosis
Prostate cancer FAAH tumor levels (but not CB1) directly
diseases
Breast cancer CB2 levels increased. Correlation with dis
Glioma CB2 levels increased with degree in gliom
Mantle cell lymphoma CB1 and CB2 levels increased and FAAH le
UV light induced skin carcinogenesis CB1 and CB2 genetic ablation decrease UV
carcinogenesis
Leukemia CB2 overexpression enhances the predisp
leukemia virus infection.
Glioma, breast cancer, skin cancer GPR55 increased levels associated with hiobservations). In many cases, these reports show that levels of
endocannabinoids and their receptors are increased in cancer, a situa-
tion that frequently correlates with tumor aggressiveness (Malﬁtano
et al., 2011). Accordingly, anandamide and 2-AG have been shown to
be over-expressed in several types of tumors including glioblastoma
multiforme (GBM), meningioma, pituitary adenoma, prostate and
colon carcinoma and endometrial sarcoma (Pisanti et al., 2013). In
addition, circulating endocannabinoid levels have been associated
with increased disease progression in amousemodel ofmetastaticmel-
anoma and in human samples of this pathology (Sailler et al., 2014). A
similar situation has been proposed for cannabinoid receptors and
endocannabinoid degrading enzymes. Thus, CB1 receptor was found
to be upregulated in Hodgkin lymphoma cells (Benz et al., 2013) and
in chemically induced cellular hepatocarcinoma (Mukhopadhyay
et al., 2015). CB1 receptor levels are also increased and correlate with
disease severity in human epithelial ovarian tumors (Messalli et al.,
2014) and have been proposed to be a factor of bad prognosis following
surgery in stage IV colorectal cancer (Jung et al., 2013).
Regarding CB2 receptor, a correlation between its expression,
histologic grade and prognosis has been demonstrated in breast cancer
(Caffarel et al., 2006) and glioma (Sanchez et al., 2001). In this latter
tumor type a combined up-regulation of CB1 and CB2 receptors has
been proposed to occur together with a decrease on the levels of the
enzymes involved in endocannabinoid degradation compared to
healthy controls (Wu et al., 2012). Similarly, expression of CB1 and
CB2 is enhanced in mantle cell lymphoma, while FAAH expression is
reduced compared to non-malignant B-cells (Ek et al., 2002; Islam
et al., 2003; Wasik et al., 2014).
Recently, a role for thenon-canonical cannabinoid receptor GPR55 in
cancer development has been described. Higher histological grades of
human glioblastomas, breast, pancreatic and skin cancers have been
reported in association with increased GPR55 expression. Moreover,
silencing of GPR55 reduced the proliferation of tumor cells in a xenograft
mouse model of glioblastoma (Andradas et al., 2011; Perez-Gomez et al.,
2013).
Altogether, these data suggest that the endocannabinoid system
may play a pro-tumorigenic role and in agreement with this hypothesis
genetic ablation of CB1 and CB2 receptors decreases UV light induced
skin carcinogenesis (Zheng et al., 2008) and CB2 receptor overexpression
enhances the predisposition to leukemia after leukemia virus infection
(Joosten et al., 2002). Moreover, genetic ablation of CB1 receptorg enzymes in human cancer.
References
(Benz et al., 2013)
(Gustafsson et al., 2008)
(Mukhopadhyay et al., 2015)
proved prognosis of patients {Xu, 2006 #378}
ease severity (Messalli et al., 2014)
llowing surgery (Jung et al., 2013)
n increases the growth of (Wang et al., 2008)
nd FAAH levels decreased (Michalski et al., 2008)
rity of disease and poor (Chung et al., 2009)
correlate with severity of the (Thors et al., 2010)
ease severity {Caffarel, 2010 #15;Caffarel, 2006 #16;Perez-Gomez
et al., 2015 #349}
as (Sanchez et al., 2001)
vels decreased (Ek et al., 2002; Islam et al., 2003; Wasik et al., 2011)
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et al., 2015).
Nevertheless, different observations also support that the
endocannabinoid system plays a tumor suppressor role in different
cancer types. Thus, genetic inactivation of CB1 receptor increases
intestinal tumor growth in a colon carcinoma genetic mouse model
(Wang et al., 2008). In line with this idea, monoacylglycerol lipase
(MAGL; the 2-AG degrading enzyme), has been shown to be highly
expressed in several types of tumors, which is associatedwith increased
migration, invasion, survival, and tumor growth (Nomura et al., 2010).
In addition, FAAH tumor levels directly correlate with the severity and
outcome of prostate adenocarcinoma (Thors et al., 2010). These data are
in line with accumulative evidences (described in the following section),
that demonstrate that cannabinoids (endogenous, phytocannabinoids or
synthetic) act as efﬁcient anti-tumoral agents in a wide range of cancer
cells.
Further studies, including those analyzing the activation of the pre-
cise signaling mechanisms involved in the regulation of cannabinoid-
induced cell death or cell proliferation upon genetic or pharmacological
manipulation of the endocannabinoid system, are therefore needed to
clarify which are the determinants for this system to act as oncogenic
or tumor suppressor.3. Cannabinoid anticancer activity
Despite the above discussed conﬂicting data relative to the role of
endocannabinoid system in tumor generation and progression, during
the last ﬁfteen years many different reports have shown that cannabi-
noid receptor agonists (derived from the plant, like THC, endogenous
like 2-AG and anandamide or synthetic — with similar or different
afﬁnity for CB1 and CB2 receptors like WIN 55,2121-2 or JWH-133)
exert antitumor effects in experimental models of cancer [reviewed in
Velasco et al. (2012)] supporting that pharmacological stimulation of
CB receptors is antitumorigenic. Nonetheless, a tumor-promoting effectBox 1
Mechanism of cannabinoid receptor-mediated cancer cell death: some im
Research performed in the last decade has permitted a better understand
anticancer action. However, a number of important observations remain
- Unlike the cell death-promoting action of cannabinoids on cancer c
under certain conditions – even enhanced by cannabinoid chall
Gomez del Pulgar et al., 2002; Salazar et al., 2009). For example
CB1 receptors) does not trigger the activation of ER stress, the up
axis or the stimulation of autophagy and apoptosis, even when
death are used (Carracedo et al., 2006b; Salazar et al., 2009).
(Carracedo et al., 2006b; Salazar et al., 2009) and other types of
when compared with their transformed counterparts (Blazquez et
1996). Thus, stimulation of cannabinoid receptors seems to be coup
and non-transformed cells. The precise molecular reasons responsi
within the cannabinoid field that still require much further research
- Another puzzling observation is that pharmacological inhibition of e
certain cancer cells (for example glioma cells) (Galve-Roperh et al.,
pancreatic (Carracedo et al., 2006a) or breast (Caffarel et al., 2006
cannabinoid anticancer actions.
- Certain cannabinoid receptor agonists trigger cancer cell death mo
tors. Thus, THC promotes cancer cell death (an effect that can be
thanWIN-55,212-2 [a cannabinoid receptor agonist which exhibits
(Pertwee et al., 2010)].
Recent observations suggest that CB2 and GPR55 receptors can form he
tivity of cannabinoids (Moreno et al., 2014). Whether some of the intrigu
binoid receptors to oligomerize with other G protein-coupled receptors, lo
couple to specific G proteins or other signaling molecules are interestingof cannabinoids has been proposed in few reports (Cudaback et al.,
2010; Hart et al., 2004; McKallip et al., 2005; Zhu et al., 2000).
Cannabinoid treatment promotes cancer cell death, impair tumor
angiogenesis and block invasion and metastasis (Velasco et al., 2012).
The molecular mechanisms that have been proposed to be involved in
cannabinoid anticancer actions have been thoroughly reviewed else-
where (Caffarel et al., 2012; Pisanti et al., 2013; Velasco et al., 2012)
and therefore will only be shortly discussed here.
3.1. Cannabinoids induce cancer cell death
The mechanism of cannabinoid anticancer action relies, at least large-
ly, on the ability of these agents to stimulate autophagy-mediated apopto-
tic cancer cell death (Velasco et al., 2012). Thus, THC binds cannabinoid
receptors, which leads to the stimulation of sphingolipid synthesis de
novo and the subsequent activation of an ER stress-related signaling
route that involves the up-regulation of the transcriptional co-activator
nuclear protein 1 (Nupr1, also named p8) and its effector the pseudo-
kinase tribbles homolog 3 (TRIB3) (Armstrong et al., 2015; Blazquez
et al., 2004; Carracedo et al., 2006a,b; Galve-Roperh et al., 2000; Gomez
del Pulgar et al., 2002; Velasco et al., 2012). The stimulation of this
pathway promotes in turn autophagy via TRIB3-mediated inhibition
of the AKT/mTORC1 axis (Salazar et al., 2009; Salazar et al., 2013).
Autophagy is considered primarily a cytoprotectivemechanism, although
its activation can also lead to cell death (Eisenberg-Lerner et al., 2009;
Galluzzi et al., 2015; Mizushima et al., 2008). A series of experiments
demonstrated that autophagy is upstream of apoptosis in themechanism
of cannabinoid-induced cell death (Armstrong et al., 2015; Salazar et al.,
2009; Vara et al., 2011).
The direct participation of the autophagy pathway in the antitumor
action of cannabinoids has been clearly demonstrated in different types
of cancer cells [namely, glioma, melanoma, pancreatic and hepatic can-
cer cells (Armstrong et al., 2015; Carracedo et al., 2006a,b; Salazar et al.,
2009; Vara et al., 2011)]. These observations support that this signaling
route could be a generalmechanismbywhich activation of CB receptorsportant unanswered questions.
ing of the intracellular signaling mechanisms underlying cannabinoid
to be clarified. For example:
ells, the viability of normal (non-transformed) cells is unaffected or –
enge (Carracedo et al., 2006b; Galve-Roperh et al., 2000, 2008;
, THC treatment of astrocytes (a cell type that expresses functional
-regulation of the p8 pathway, the inhibition of the AKT–mTORC1
concentrations of THC higher than those that promote glioma cell
Similar results were obtained with primary embryonic fibroblasts
non-transformed cells expressing functional cannabinoid receptors
al., 2006; Caffarel et al., 2006; Casanova et al., 2003; Chan et al.,
led to the activation of different signalingmechanisms in transformed
ble for this differences remain as an one of the unanswered questions
in order to be clarified.
ither CB1 or CB2 receptors prevents THC-induced cell death at least in
2000; Lorente et al., 2011), whereas in, hepatic (Vara et al., 2011),
) carcinoma cells, antagonists of CB2 but not of CB1 receptors inhibit
re efficiently than others exhibiting even higher affinity for CB recep-
blocked using of CB receptors antagonists) at lower concentrations
in binding assays higher affinity than THC for CB1 and CB2 receptors
teromers— and that these structures can modify the antitumoral ac-
ing effects described above can be explained by the ability of canna-
cate in precise domains in the plasma membrane (or in organelles) or
possibilities that require much further research.
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of them cell type speciﬁc) may cooperate with this pathway to trigger
cancer cell death (Vara et al., 2011; Caffarel et al., 2006, 2012;
Guzman, 2003; Sarfaraz et al., 2008; Vara et al., 2013). (see also Box 2).
Cannabidiol [CBD; a plant-derived cannabinoid with low afﬁnity for
cannabinoid receptors; (Pertwee, 2009)], and other marijuana-derived
cannabinoids (Ligresti et al., 2006) have also been shown to trigger
apoptosis in cancer cells. CBD produces these anticancer actions – at
least in part – via enhanced production of reactive oxygen species
(Massi et al., 2008; Shrivastava et al., 2011). It has also been proposed
that CBD may activate TRPV2 receptors to promote cancer cell death
(Nabissi et al., 2012).
3.2. Cannabinoids inhibit angiogenesis, invasion and metastasis
In addition to the above-described cancer cell death promoting
effect of cannabinoids, treatment with these compounds has been
shown to normalize tumor vasculature. These effects seem to rely on
the ability of cannabinoids to inhibit the stimulation of the vascular
endothelial growth factor (VEGF) pathway. Thus, various components
of the VEGF-activated pathway, such as the active forms of its best-
established receptors (VEGFR1 and VEGFR2), have been shown to be
down-regulated in response to treatment with cannabinoids in different
cancer types (Casanova et al., 2003; Blazquez et al., 2003, 2004; Portella
et al., 2003). Likewise, cannabinoid receptor activation inhibits migration
and proliferation, and induces apoptosis in vascular endothelial cells
(Blazquez et al., 2003; Pisanti et al., 2007) which might also contribute
to the antiangiogenic effect of cannabinoids.
In addition, cannabinoids have been shown to reduce the formation of
distant tumor masses in animal models of spontaneous and induced
metastasis. Moreover, these compounds inhibit migration, adhesion and
invasiveness of different types of cancer cells (Blazquez et al., 2008;
Grimaldi et al., 2006; Preet et al., 2008; Qamri et al., 2009; Ramer and
Hinz, 2008). This anti-metastatic activity of cannabinoids relies, at least
in part, on the regulation of extracellular proteases and their inhibitors
(Blazquez et al., 2008; Ramer and Hinz, 2008). Several observations sup-
port that the ER stress-related signaling pathway involved in theBox 2
Different pharmacological approaches to target cancer cells with cannab
Cannabinoid agonists or enhancers of endocannabinoid tone?
Administration of endocannabinoids or inhibitors of endocannabinoid-de
types of tumor xenografts (Bifulco et al., 2001; Ligresti et al., 2003) and
receptors for anticancer purposes. However, as discussed in sect
endocannabinoid-degrading enzymes, in the control of tumor gener
endocannabinoid tone only has mild anti-tumor effects in mice and since
yet for use in humans, clinical studies aimed at analyzing the efficacy o
plant-derived or synthetic agonists of cannabinoid receptors rather than o
Cannabis extracts or pure cannabinoids?
The long-known therapeutic properties of Cannabis sativa – including ame
have led to the authorization of the medical use of this plant and its extra
cannabinoids present in marijuana may contribute to the attenuation of T
are more prone to standardization than complex molecular cocktails. Thu
actions of cannabinoids in patients were performed comparatively with
amounts of THC, CBD and other cannabinoids.
Which routes of cannabinoid administration?
Smoking is the most frequent route of administration of self-medicated a
from the plant are rapidly absorbed by inhalation. However, smoking i
cannabinoid was assayed as an anti-caner agent, THC was administered
Nevertheless, this route of administration has many obvious limitations. C
sules or using an oro-mucosal spray (Pertwee, 2009). Preclinical animal mo
administration of cannabinoids effectively reduces tumor growth (autho
clinical studies directed at determining the efficacy of cannabinoids as antstimulation of autophagy-mediated cancer cell death may also play a
role in the control of these actions of cannabinoids (Blazquez et al.,
2004, 2008).
Of note, CBD exerts a signiﬁcant anticancer effect – and speciﬁcally
the inhibition of invasiveness and mestastasis – in different animal
models of cancer acting independently of cannabinoid receptors. This
effect of CBD relies – at least partially – on the downregulation of ID-1
(transcription factor inhibitor of DNA binding-1) (McAllister et al.,
2011; Murase et al., 2014; Soroceanu et al., 2012).
4. Mechanisms of resistance to cannabinoid anticancer action
Today it is well established that themolecular characteristics of each
individual tumor and patient determine the responsiveness to antican-
cer therapies. Although much further research is still required to clarify
this issue in the case of cannabinoids, work performed in our laboratory
supports that – at least in gliomas – the differences in the expression of a
particular set of genes rather than in the levels of CB receptors deter-
mine the sensitivity to THC-induced cell death, (Lorente et al., 2011).
We found that increased expression of midkine [MDK; (Kadomatsu,
2005; Mirkin et al., 2005), one of the genes that is strongly up-
regulated in cannabinoid-resistant glioma cells] is associated with a
lower overall survival of glioblastoma patients (Lorente et al., 2011).
MDK promotes resistance to THC-induced cell death via stimulation of
one of its target receptors, the anaplastic lymphoma tyrosine kinase
receptor [ALK (Palmer et al., 2009)] which abrogates the induction of
autophagy-mediated glioma cell death by THC. Supporting the potential
therapeutic relevance of these ﬁndings, pharmacological inhibition
of ALK or MDK knock-down abolishes the resistance to cannabinoid
treatment of tumor xenografts derived from THC-resistant glioma cells
(Lorente et al., 2011). Altogether, these observations support that
stimulation of the MDK–ALK axis promotes resistance to cannabinoid
anticancer action in glioblastoma and paves the way for the develop-
ment of anticancer therapies based on the combined administration of
THC and inhibitors of the MDK–ALK axis (Fig. 1). In line with this idea,
ALK inhibitors – which have started to be assayed in clinical trials
for the management of non-small-cell lung cancer and other types ofinoids.
grading enzymes has been shown to reduce the growth of different
, therefore, could be a reasonable strategy for targeting cannabinoid
ion 2, the role of the endocannabinoid system, including the
ation and progression is not well understood. Since enhancing
no inhibitor of endocannabinoid degradation has been approved as
f cannabinoids as anti-tumor agents should be based on the use of
n endocannabinoids or inhibitors of endocannabinoid degradation.
lioration of symptoms associatedwith cancer and its chemotherapy –
cts in several countries. As mentioned in the text, some of the other
HC psychoactive-side effects (Pertwee, 2009) However, pure drugs
s, it would be ideal that studies aimed at investigating the anticancer
both pure substances and cannabis extracts containing controlled
nd recreational marijuana. Thus, THC and other cannabinoids derived
s an unattractive clinical option. In the first clinical trial in which a
locally (intracranial delivery to GBM patients) (Guzman et al., 2006).
urrently-available cannabis-based medicines are administered as cap-
dels have yielded data indicating that systemic (oral or intraperitoneal)
r's unpublished observations). Thus, it seems reasonable that future
i-cancer agents use oral or oro-mucosal routes of administration.
Fig. 1. Possible strategies aimed at optimizing cannabinoid-based therapies against gliomas. Resistance of glioma cells to cannabinoid-induced cell death relies, at least in part, on the en-
hanced expression of the growth factor midkine (MDK) and the subsequent activation of the anaplastic lymphoma receptor tyrosine kinase (ALK). Enhanced expression of amphiregulin
(AREG, a heparin-bound ligand of the EGFR) can promote resistance to THC antitumor action via ERK stimulation. Combination of THCwith pharmacological inhibitors of ALK (or genetic
inhibition of MDK) enhances cannabinoid action in resistant tumors. Combinations of cannabinoids with classical chemotherapeutic drugs such as the alkylating agent temozolomide
[TMZ; the benchmark agent for themanagement of glioblastoma (Lonardi et al., 2005; Stupp et al., 2005)] produce a strong anticancer action in animalmodels. Other strategies to enhance
cannabinoid anticancer action could be combining cannabinoids with endoplasmic reticulum (ER) stress and/or autophagy inducers or with inhibitors of the AKT-mechanistic target of
rapamycin C1 (mTORC1) axis. Abs: antibodies; EGFR: epidermal growth factor receptor; ERK: extracellular signal-regulated kinase; GF: growth factors; RTK: receptor tyrosine kinase;
TRIB3: tribbles 3; VEGF: vascular endothelial growth factor.
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proposed to be of potential utility in glioblastoma multiforme (GBM)
(Wallace et al., 2013). Following this line of reasoning, the ALK and
the MET proto-oncogene, receptor tyrosine kinase (MET) inhibitor
Crizotinib is currently being evaluated in combinationwith radiotherapy
and temozolomide [TMZ; the benchmark agent for the management of
glioblastoma (Stupp et al., 2005)] in a Phase 1b clinical study in adult
patients with newly diagnosed glioblastoma (NCT02270034) which
may facilitate the development of future studies combining this inhibi-
tor with cannabinoids. A second generation of ALK inhibitors with a
lower risk of developing drug resistance in patients, such as Ceritinib
or Alectinib, is being already evaluated in clinical studies (Pall, 2015).
Alternative approaches to inhibit MDK–ALK axis could also include the
use of humanized antibodies against MDK or its receptor ALK.
It is worth noting that other growth factors [such as the heparin-
bound epidermal growth factor receptor (EGFR) ligand amphiregulin]
have been implicated in the resistance to cannabinoid antitumor action
(Lorente et al., 2009; Hart et al., 2004). Thus pharmacological blockade
of EGFR, (Lorente et al., 2009) enhances the cell death-promoting action
of THC in cultures of glioma cells. These observations suggest that
targeting EGFR pathway may also be a therapeutic strategy to enhance
cannabinoid anticancer activity. Whether these or other mechanisms
may play a relevant role in promoting resistance to cannabinoid anti-
cancer action in other tumor types remain to be investigated.
5. Towards the use of cannabinoid-based combinational therapies
Current strategies to ﬁght cancer are based on the use of combina-
tional anticancer therapies as this approach permits the simultaneous
targeting of tumor growth, at different levels. In agreement with this
line of reasoning, the combined administration of cannabinoids with
other anticancer agents has been shown to act synergistically to inhibit
tumor growth. Accordingly, treatment with THC and TMZ exerts a
strong anti-cancer action in xenografts generated with glioma cells.Importantly this effect also takes place in TMZ-resistant tumors
(Torres et al., 2011). Likewise, mice treated with TMZ and THC did not
show signs of toxicity (Torres et al., 2011). Most glioblastoma patients
are treated with TMZ, and therefore these ﬁndings support that the
combined administration of TMZ and cannabinoids could be therapeu-
tically exploited for the management of glioblastoma (Fig. 1).
Likewise, another study performed with pancreatic cancer cells
showed that gemcitabine (the benchmark agent for the treatment of
pancreatic cancer) acted synergistically with different cannabinoid
agonists to reduce cell viability (Donadelli et al., 2011). Other studies
showed that anandamide andHU-210 increase the antineoplastic activ-
ity of paclitaxel (Miyato et al., 2009) and 5-ﬂuorouracil (Gustafsson
et al., 2009).
Another approach has been to assay the anticancer activity of the
combination of THC and CBD. Thus, the administration of these two
agents enhances the anticancer activity of THC and decreases the
doses of THC required to produce tumor growth-inhibition (Marcu
et al., 2010; Torres et al., 2011). Moreover, the combined administration
of THC, CBD and TMZ produces a very strong decrease in the growth of
xenografts generated with glioma cells even when low doses of THC
are employed (Torres et al., 2011). Furthermore the administration of
THC and CBD also enhanced the anticancer effects of radiation in
an orthotopic murine glioma model (Scott et al., 2014). Since, CBD
alleviates some of the undesired side effects of THC (for example
discoordination, convulsions, and psychotic events), its administration
in combination with THCmay help to improve the tolerability to medi-
cines containing this agent or other cannabinoid receptor agonists
(Pertwee, 2009). Following this line of reasoning it is worth noting
that C. sativa produces ~108 different cannabinoids and, apart from
CBD, some of them may help to reduce the undesired side-effects of
THC or have other therapeutic activities (Pertwee, 2009). Therefore, in
addition to the use of pure substances (such as THC and CBD) for the de-
velopment of clinical studies to investigate the efﬁcacy of cannabinoids
as anticancer agents, one possible additional approach could be using
264 G. Velasco et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016) 259–266cannabis extracts with precisely-deﬁned amounts of THC, CBD and
other cannabinoids.
6. Towards the development of clinical studies to test the efﬁcacy of
cannabinoids as anticancer agents
Despite the remarkable amount of preclinical research on the poten-
tial therapeutic applications of cannabinoids the use of cannabis-based
medicines in the clinical practice is restricted to palliative uses in a
few diseases. Nevertheless, preclinical data accumulated during the
last decade has stimulated the interest in developing additional clinical
studies aimed at investigating the potential therapeutic value of these
compounds in different diseases and speciﬁcally their potential as
anticancer agents. The ﬁrst of this studies was a pilot Phase I clinical
trial in which 9 patients with actively-growing recurrent glioblastoma
that had previously failed standard therapy underwent intracranial
THC administration (Guzman et al., 2006). Cannabinoid delivery
under these conditions was safe. Likewise, signiﬁcant undesired effects
were not observed in the patients of the study. In addition, analysis
of the results obtained in this study suggested that some patients
responded – at least partially – to THC treatment (Guzman et al.,
2006). Importantly, analyses of samples obtained from 2 patients in
this study before and after THC treatment indicated that administration
of this cannabinoid correlated with the activation of the mechanisms
that had been previously shown to be involved in the anticancer activity
of THC in animal models of cancer [for example stimulation of autoph-
agy and apoptosis (Carracedo et al., 2006b; Guzman et al., 2006;
Salazar et al., 2009), inhibition of cell proliferation (Guzman et al.,
2006), decreased VEGF signaling (Blazquez et al., 2004) and MMP-2
down-regulation (Blazquez et al., 2008)]., These encouraging ﬁndings
fostered the interest on the utilization of cannabinoids in cancer thera-
pies. However, they also underlined the need for additional preclinical
and clinical studies aimed at optimizing the use of cannabinoids (see
Box 2).
In line with this idea and based on the observations described in
the previous section showing that the combination of THC, CBD and
TMZ enhances the anticancer activity of each of these antineoplastic
agents (Scott et al., 2014; Torres et al., 2011), a Phase 1/2 clinical
study in recurrent GBM patients is being conducted to assess the safety
and effectiveness of the administration of the cannabinoid-based
medicine Sativex concomitantly with TMZ (NCT01812603 and
NCT01812616). A high percentage of newly diagnosed GBM presents
innate resistance to TMZ (Mrugala, 2013). This resistance has been
related with several molecular alterations, including the methylation
of the methylguanine-DNA methyltransferase (MGMT) promoter
(Hegi et al., 2005). Preclinical data support that the combination of
cannabinoids and TMZ exerts a strong anticancer action even when
MGMT is over-expressed (Torres et al., 2011) thereby suggesting that
this type of therapy might potentially help to improve the overall
response to TMZ treatment in glioblastoma.
Synthetic cannabinoids are also being evaluated in clinical studies.
For example, dexanabinol, [an enantiomer HU-210 (a mixed CB1/CB2
cannabinoid receptor agonist) which does not bind with signiﬁcant
afﬁnity to cannabinoid receptors but instead acts a NMDA receptor
antagonist (Feigenbaum et al., 1989)], is currently undergoing Phase 1
trials for the treatment of brain cancer and advanced solid tumors
(NCT01489826).
7. Conclusions and future directions
Despite the existence of conﬂicting reports relative to the role of
the endocannabinoid system in cancer generation and progression
and several reports pointing to a possible tumor-promoting immuno-
suppressive role of cannabinoids (Cudaback et al., 2010; Hart et al.,
2004; McKallip et al., 2005; Zhu et al., 2000) a large body of scientiﬁc
evidences strongly support THC and other cannabinoid agonists exertanticancer actions in preclinical models of cancer (including immuno-
competent mice) through a well-established mechanism of action.
There is also a good evidence that cannabinoids enhance the anticancer
activity of TMZ andALK inhibitors in animalmodels of glioma. These ob-
servations provide preclinical proof-of-concept that cannabinoids could
enhance the efﬁcacy of classical cytotoxic drugs at least in glioblastoma
(Fig. 1). However, additional studies are required to analyze the efﬁcacy
of these drug combinations in other cancer types as well as to identify
additional cannabinoid-based drug combinations that could be useful
for the treatment of glioma or other types of cancer. Likewise, further
research is required to identify the precise molecular cross-talk
mechanisms that become activated upon exposure of cancer cells to
cannabinoids in combination with different chemotherapeutic agents.
Regarding patient stratiﬁcation, one important step forward would
be to identify which patients are potentially responsive to cannabinoid
treatment. To this aim, it would be desirable that future clinical trials
aimed at analyzing the anticancer activity of cannabinoid-based medi-
cines would include translational studies in which speciﬁc biomarkers
associated to a better or worse response to cannabinoid treatment
could be identiﬁed.
In conclusion there exist solid scientiﬁc evidences supporting that
cannabinoids exhibit a remarkable anticancer activity in preclinical
models of cancer. Since these agents also show an acceptable safety
proﬁle, clinical studies aimed at testing them as single agents or in
combinational therapies are urgently needed. Results from these
studies are essential to clarify whether cannabinoids (and speciﬁcally
cannabinoid-based medicines) could be helpful in the ﬁght of cancer.
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